Tumor Ablation Market

7500+ companies worldwide approach us every year for their revenue growth initiatives

Global top 2000 strategist rely on us for their growth strategies.

80% of fortune 2000 companies rely on our research to identify new revenue sources.

30000 High Growth Opportunities

95% renewal rate

KNOW MORE

Tumor Ablation Market Size, Share & Trends by Technology (Radiofrequency, Microwave, Laser, IRE, HIFU, Cryoablation), Product (Generators, Probes), Mode (Surgical, Laparoscopic, Percutaneous), Cancer (Liver, Lung, Bone), End User (Hospitals, Clinic) & Region - Global Forecast to 2029

FREE BROCHURE FREE SAMPLE REPORT

Report Code: MD 3271 May, 2024, by marketsandmarkets.com

Tumor Ablation Market Size, Share & Trends

The size of global tumor ablation market in terms of revenue was estimated to be worth $0.8 billion in 2024 and is poised to reach $1.4 billion by 2029, growing at a CAGR of 10.0% from 2024 to 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

Major driver is the rising incidence of cancer, particularly among the aging population. Additionally, advancements in probe/electrode technology have led to the increasing demand for ablation systems, which offer precise ablation and minimal damage to healthy tissue. Moreover, rising awareness about early detection and rising disposable incomes, coupled with expanding access to healthcare services in emerging markets, further fuel the demand for tumor ablation.

Tumor Ablation Market Trends

Tumor Ablation Market

To know about the assumptions considered for the study, Request for Free Sample Report

Tumor Ablation Market

e- Estimated; p- Projected

Tumor Ablation Market Dynamics

Driver: Increasing cancer incidence and rising geriatric population

Tumor ablation market is primarily driven by the rising incidence of cancer globally. Tumor ablation is widely used for the treatment of lung cancer, liver cancer, prostate cancer, bone cancer, and kidney cancer among others. According to WHO, cancer was the major cause of death globally in 2020 -accounted for around 10 mn deaths. Emerging economies in Asia, Africa, and Oceania reported 55% of the 18.1 million cancer cases diagnosed. With the continuous rise in the global cancer patient population, there is expected to be a significant increase in demand for tumor ablation procedures during the forecast period.

Restraint: Increasing cancer incidence and rising geriatric population

High cost of tumor ablation systems is one of the restrains in tumor ablation market. Premium product pricing hinders the adoption in emerging countries. Small healthcare facilities rely on third-party payers to reimburse the costs incurred in diagnostic, screening, and therapeutic procedures. The high cost of the equipment makes it difficult for most hospitals in emerging economies to afford this technology. Hence, smaller end users are hesitant to invest in this equipment.

Opportunity: Rising healthcare expenditure across emerging economies

Growing healthcare expenditure in emerging nations such as China, India, Brazil, and Mexico are expected to offer lucrative opportunities for tumor ablation market. For instance, according to GLOBOCAN 2020 data, over 50% of the global cancer population resides in emerging economies. Increasing government initiatives towards providing advanced healthcare services and improving reimbursement coverage support the adoption of tumor ablation devices. rapid increase in the per-capita healthcare expenditure and the rising public demand for affordable healthcare in emerging economies to further expected to drive the demand for ablation systems in developing countries.

Challenge: Rising adoption of refurbished tumor ablation systems

Small scale end users specifically in developing countries often opt for refurbished alternatives as a cost-effective solution. Refurbished systems are sold at a fraction of the cost of new equipment Refurbished systems are sold at a fraction of the cost of new equipment. Due to similar functioning and affordable cost the adoption of refurbished systems is experiencing a surge in the adoption. This poses a challenge for smaller manufacturers who are struggling to keep up and is expected to impact the market growth.

Tumor Ablation Industry Ecosystem.

Tumor Ablation Market Ecosystem

By Technology, the radiofrequency ablation segment accounted for the largest share of the tumor ablation industry in 2022.

Based on technology, the tumor ablation market is segmented into radiofrequency ablation, microwave ablation, high intensity focused ultrasound (HIFU), cryoablation, and other technologies. In 2023, the radiofrequency ablation segment accounted for the largest market share. Rising awareness of proactive health and expansion of market players fuel the growth of tumor ablation market.

By Product Type, the generators segment of the tumor ablation industry to register significant growth in the near future.

Based on product type, the tumor ablation market is segmented into generators probes and electrodes. The generators segment accounted for the largest market share in 2023. The demand for minimally invasive procedures is increasing due to the emphasis on improving quality of life. Additionally, favorable regulatory scenarios and a surge in oncological surgeries contribute to the rising adoption of tumor ablation systems.

The laparoscopic ablation segment for mode of treatment segment is expected to register a higher CAGR of the tumor ablation industry forecast period.

Based on mode of treatment, the tumor ablation market is segmented into laparoscopic ablation, surgical ablation, and percutaneous ablation. Increasing collaboration between industry players and healthcare providers and integration of ablation systems with other treatment modalities contribute to the growth of this segment. Laparoscopic ablation has improved benefits as compared to other modes of treamtnets. Factors such as reduced pain, greater visibility due to laparoscopic cameras, quick recovery, and shorter stays at the hospitals contribute to the exponential growth of this segment.

The liver cancer segment for application segment held the largest share of the tumor ablation industry in 2023.

Based on application, the tumor ablation market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other applications. Liver cancer segment held largest share of the market in 2023 and is also expected to register a significant growth rate from 2024 to 2029. Increasing adoption of image-guided therapies and increasing funding opportunities for cancer research are driving the adoption.

By end user, the hospitals and clinic centers segment of the tumor ablation industry held the largest share.

The tumor ablation market is segmented by end users into hospitals and clinics, cancer care centers, and other end users. However, the cancer care centers segment is expected to grow at the highest CAGR during the forecast period. The rise in number of chronic diseases, including cancer, increasing cancer diagnostic procedures in the hospitals globally, and the potential of benefits of ablation observed in patients with early stage cancer have contributed to the growth of this segment.

By region, North America is expected to be the largest market of the tumor ablation industry by 2029.

The US and Canada accounted for a significant market share in 2023. North America's faster growth in the tumor ablation market can be attributed to its technological leadership, robust healthcare infrastructure, favorable insurance coverage, growing funding and grants for developing advanced medical equipment, favorable regulatory scenario, strategic research collaboration, and a supportive market environment fostering innovation.

Tumor Ablation Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2023, prominent players in the market are Johnson & Johnson MedTech (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US), IceCure Medical Ltd. (Israel), Bioventus Inc. (US).

Scope of the Tumor Ablation Industry:

Report Metric	Details
Market Revenue in 2024	$0.8 billion
Projected Revenue by 2029	$1.4 billion
Revenue Rate	Poised to Grow at a CAGR of 10.0%
Market Driver	Increasing cancer incidence and rising geriatric population
Market Opportunity	Rising healthcare expenditure across emerging economies

This report has segmented the global tumor ablation market to forecast revenue and analyze trends in each of the following submarkets:

By Technology

Radiofrequency Ablation
Microwave Ablation
Cryoablation
High-intensity Focused Ultrasound
Other Technologies

By Product Type

Generators
Probes/electrodes

By Mode Of Treatment

Surgical Ablation
Percutaneous Ablation
Laparoscopic Ablation

By Application

Liver Cancer
Lung Cancer
Kidney Cancer
Bone Cancer
Other Applications

By End User

Hospitals & clinics
Cancer care centers
Other End Users

By Region

North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America

Recent Developments of the Tumor Ablation Industry:

In May 2023, Varian launched the Isolis cryoprobe for CryoCare systems. These are disposable probes with improved efficiency and precision for cryoablation. It helps with tumor ablation. They also support accuracy and help to reduce procedure time.
In April 2023, AngioDynamics extended its partnership with Cardiva. The collaboration aims to introduce AngioDynamics’ oncology products across Europe.

Frequently Asked Questions (FAQ):

What is the projected market revenue value of the global tumor ablation market?

The global tumor ablation market boasts a total revenue value of $1.4 billion by 2029.

What is the estimated growth rate (CAGR) of the global tumor ablation market?

The global tumor ablation market has an estimated compound annual growth rate (CAGR) of 10.0% and a revenue size in the region of $0.8 billion in 2024. .

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 27)

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

1.3.2 YEARS CONSIDERED

1.3.3 CURRENCY CONSIDERED

1.4 RESEARCH LIMITATIONS

1.5 KEY STAKEHOLDERS

1.6 SUMMARY OF CHANGES

1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 31)

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY RESEARCH

2.1.2 PRIMARY RESEARCH

2.1.2.1 Primary sources

2.1.2.2 Key industry insights

2.1.2.3 Breakdown of primaries

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.2 MARKET SIZE ESTIMATION

FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING

2.2.1 BOTTOM-UP APPROACH

2.2.1.1 Approach 1: Company revenue estimation approach

FIGURE 5 TUMOR ABLATION MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)

2.2.1.2 Approach 2: Customer-based market estimation

FIGURE 6 TUMOR ABLATION MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

2.2.1.3 Growth forecast

2.2.1.4 CAGR projections

FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS

2.3 DATA VALIDATION APPROACH

FIGURE 8 DATA TRIANGULATION METHODOLOGY

2.4 MARKET SHARE ASSESSMENT

2.5 STUDY ASSUMPTIONS

2.6 GROWTH RATE ASSUMPTIONS

2.7 RISK ASSESSMENT

2.8 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 43)

FIGURE 9 TUMOR ABLATION MARKET, TECHNOLOGY, 2024 VS. 2029 (USD MILLION)

FIGURE 10 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)

FIGURE 11 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2024 VS. 2029 (USD MILLION)

FIGURE 12 TUMOR ABLATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)

FIGURE 13 TUMOR ABLATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)

FIGURE 14 TUMOR ABLATION MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS (Page No. - 47)

4.1 TUMOR ABLATION MARKET OVERVIEW

FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH

4.2 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY

FIGURE 16 MICROWAVE ABLATION SEGMENT TO REGISTER SIGNIFICANT GROWTH IN NORTH AMERICA DURING FORECAST PERIOD

4.3 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION

FIGURE 17 LIVER CANCER SEGMENT TO DOMINATE MARKET IN EUROPE DURING FORECAST PERIOD

4.4 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER

FIGURE 18 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO HOLD LARGEST SHARE IN ASIA PACIFIC MARKET

4.5 GEOGRAPHIC SNAPSHOT OF TUMOR ABLATION MARKET

FIGURE 19 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 50)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 20 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Increasing cancer incidence and rising geriatric population

5.2.1.2 Rising focus on minimally invasive procedures

5.2.1.3 Technological advancements in field of tumor ablation

5.2.1.4 Rising number of awareness campaigns and early detection

5.2.2 RESTRAINTS

5.2.2.1 High cost of tumor ablation systems

5.2.2.2 Unfavorable regulatory scenario

5.2.3 OPPORTUNITIES

5.2.3.1 Rising healthcare expenditure across emerging economies

5.2.3.2 Increasing number of hospitals

5.2.4 CHALLENGES

5.2.4.1 Rising adoption of refurbished tumor ablation systems

5.2.4.2 Hospital budget cuts

5.3 REGULATORY ANALYSIS

5.3.1 KEY REGULATORY BODIES AND GOVERNMENT AGENCIES

TABLE 1 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES

TABLE 2 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES

TABLE 3 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES

TABLE 4 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES

TABLE 5 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES

5.3.2 KEY REGULATORY GUIDELINES

5.3.2.1 US

TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION

TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS

FIGURE 21 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES

5.3.2.2 Canada

TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS

FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES

5.3.2.3 Europe

FIGURE 23 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES

5.3.2.4 Asia Pacific

5.3.2.4.1 Japan

TABLE 9 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES

TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)

5.3.2.4.2 China

TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES

5.3.2.4.3 India

TABLE 12 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES

5.3.2.5 Latin America

5.3.2.5.1 Brazil

5.4 REIMBURSEMENT SCENARIO

TABLE 13 MEDICAL REIMBURSEMENT CPT CODES FOR MICROWAVE AND RADIOFREQUENCY ABLATION PROCEDURES IN US (EFFECTIVE JANUARY 1, 2022)

5.5 VALUE CHAIN ANALYSIS

5.5.1 RESEARCH & DEVELOPMENT

5.5.2 MANUFACTURING & ASSEMBLY

5.5.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES

FIGURE 24 TUMOR ABLATION MARKET: VALUE CHAIN ANALYSIS

5.6 SUPPLY CHAIN ANALYSIS

5.6.1 PROMINENT COMPANIES

5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES

5.6.3 END USERS

FIGURE 25 TUMOR ABLATION MARKET: SUPPLY CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

FIGURE 26 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS

TABLE 14 TUMOR ABLATION MARKET: ROLE IN ECOSYSTEM

5.8 INVESTMENT & FUNDING SCENARIO

FIGURE 27 NUMBER OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022

FIGURE 28 VALUE OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)

5.9 PRICING ANALYSIS

FIGURE 29 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY TECHNOLOGY

FIGURE 30 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY REGION

TABLE 15 AVERAGE SELLING PRICE OF TUMOR ABLATION SYSTEMS, BY REGION, 2021–2023

5.10 TRADE ANALYSIS

TABLE 16 IMPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)

TABLE 17 EXPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND)

5.11 PATENT ANALYSIS

FIGURE 31 PATENT DETAILS FOR TUMOR ABLATION MARKET (JANUARY 2013– DECEMBER 2023)

5.12 PORTER’S FIVE FORCE ANALYSIS

TABLE 18 PORTER’S FIVE FORCES ANALYSIS: TUMOR ABLATION MARKET

5.12.1 THREAT OF NEW ENTRANTS

5.12.2 THREAT OF SUBSTITUTES

5.12.3 BARGAINING POWER OF SUPPLIERS

5.12.4 BARGAINING POWER OF BUYERS

5.12.5 INTENSITY OF COMPETITIVE RIVALRY

5.13 KEY CONFERENCES & EVENTS IN 2024–2025

TABLE 19 LIST OF MAJOR CONFERENCES & EVENTS IN TUMOR ABLATION MARKET, 2024–2025

5.14 CASE STUDY ANALYSIS

TABLE 20 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY

TABLE 21 CASE STUDY 2: ABLATION OF LOCALIZED RENAL TUMOR

5.15 TECHNOLOGY ANALYSIS

5.15.1 KEY TECHNOLOGIES

5.15.1.1 Radiofrequency ablation and microwave ablation

5.15.1.2 Cryoablation

5.15.2 COMPLEMENTARY TECHNOLOGIES

5.15.2.1 Laparoscopy

5.15.2.2 Diagnostic imaging

5.15.3 ADJACENT TECHNOLOGIES

5.15.3.1 Electrosurgery

5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

FIGURE 32 REVENUE SHIFT IN TUMOR ABLATION MARKET

5.17 KEY STAKEHOLDERS & BUYING CRITERIA

5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES

TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)

5.17.2 BUYING CRITERIA

FIGURE 34 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS

TABLE 23 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS

5.18 UNMET NEEDS & KEY PAIN POINTS

TABLE 24 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS

6 TUMOR ABLATION MARKET, BY TECHNOLOGY (Page No. - 80)

6.1 INTRODUCTION

TABLE 25 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

6.2 RADIOFREQUENCY ABLATION

6.2.1 LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH

TABLE 26 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)

6.3 MICROWAVE ABLATION

6.3.1 ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH

TABLE 27 MICROWAVE ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)

6.4 CRYOABLATION

6.4.1 HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET

TABLE 28 CRYOABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)

6.5 HIGH-INTENSITY-FOCUSED ULTRASOUND (HIFU)

6.5.1 TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND ABLATION TO FAVOR MARKET GROWTH

TABLE 29 HIGH-INTENSITY-FOCUSED ULTRASOUND MARKET, BY REGION, 2022–2029 (USD MILLION)

6.6 OTHER TECHNOLOGIES

TABLE 30 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)

7 TUMOR ABLATION MARKET, BY PRODUCT TYPE (Page No. - 86)

7.1 INTRODUCTION

TABLE 31 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)

TABLE 32 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (UNITS)

7.2 GENERATORS

7.2.1 RISING ADOPTION OF TUMOR ABLATION SYSTEMS TO PROPEL MARKET GROWTH

TABLE 33 TUMOR ABLATION GENERATORS MARKET, BY REGION, 2022–2029 (USD MILLION)

7.3 PROBES/ELECTRODES

7.3.1 RADIOFREQUENCY ABLATION PROBES

7.3.1.1 Rising adoption of radiofrequency ablation systems for multiple applications to propel market growth

TABLE 34 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)

7.3.2 MICROWAVE ABLATION PROBES

7.3.2.1 Increasing cancer prevalence and precise ablation to boost adoption

TABLE 35 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)

7.3.3 OTHER PROBES/ELECTRODES

TABLE 36 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2022–2029 (USD MILLION)

8 TUMOR ABLATION MARKET, BY MODE OF TREATMENT (Page No. - 91)

8.1 INTRODUCTION

TABLE 37 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)

8.2 SURGICAL ABLATION

8.2.1 RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET

TABLE 38 TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2029 (USD MILLION)

8.3 LAPAROSCOPIC ABLATION

8.3.1 IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND

TABLE 39 TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2029 (USD MILLION)

8.4 PERCUTANEOUS ABLATION

8.4.1 SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT

TABLE 40 TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2029 (USD MILLION)

9 TUMOR ABLATION MARKET, BY APPLICATION (Page No. - 96)

9.1 INTRODUCTION

TABLE 41 TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

9.2 LIVER CANCER

9.2.1 PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET

TABLE 42 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022–2029 (USD MILLION)

9.3 LUNG CANCER

9.3.1 RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET

TABLE 43 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)

9.4 KIDNEY CANCER

9.4.1 RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE OF HEALTHY TISSUE TO DRIVE ADOPTION

TABLE 44 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)

9.5 BONE CANCER

9.5.1 RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH

TABLE 45 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022–2029 (USD MILLION)

9.6 OTHER APPLICATIONS

TABLE 46 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)

10 TUMOR ABLATION MARKET, BY END USER (Page No. - 101)

10.1 INTRODUCTION

TABLE 47 TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)

10.2 HOSPITALS & CLINICS

10.2.1 INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET

TABLE 48 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)

10.3 CANCER CARE CENTERS

10.3.1 GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET

TABLE 49 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)

10.4 OTHER END USERS

TABLE 50 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)

11 TUMOR ABLATION MARKET, BY REGION (Page No. - 105)

11.1 INTRODUCTION

TABLE 51 TUMOR ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)

11.2 NORTH AMERICA

FIGURE 35 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT

TABLE 52 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 53 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

TABLE 54 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)

TABLE 55 NORTH AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)

TABLE 56 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 57 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)

11.2.1 NORTH AMERICA: RECESSION IMPACT

11.2.2 US

11.2.2.1 Rising prevalence of cancer to propel market growth

TABLE 58 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.2.3 CANADA

11.2.3.1 Growing burden of cancer to support market growth

TABLE 59 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.3 EUROPE

TABLE 60 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 61 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

TABLE 62 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)

TABLE 63 EUROPE: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)

TABLE 64 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 65 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)

11.3.1 EUROPE: RECESSION IMPACT

11.3.2 GERMANY

11.3.2.1 Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects

TABLE 66 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.3.3 FRANCE

11.3.3.1 Growing geriatric population to support market growth in France

TABLE 67 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.3.4 UK

11.3.4.1 Growing target patient population to support market growth in UK

TABLE 68 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.3.5 ITALY

11.3.5.1 Rising awareness to support market growth

TABLE 69 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.3.6 SPAIN

11.3.6.1 Increasing government funding for research to support market growth

TABLE 70 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.3.7 REST OF EUROPE

TABLE 71 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.4 ASIA PACIFIC

FIGURE 36 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT

TABLE 72 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 73 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

TABLE 74 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)

TABLE 75 ASIA PACIFIC: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)

TABLE 76 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 77 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)

11.4.1 ASIA PACIFIC: RECESSION IMPACT

11.4.2 JAPAN

11.4.2.1 Presence of universal healthcare reimbursement scenario to drive market growth

TABLE 78 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.4.3 CHINA

11.4.3.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth

TABLE 79 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.4.4 INDIA

11.4.4.1 Ongoing modernization and infrastructure development in India to support market growth

TABLE 80 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.4.5 AUSTRALIA

11.4.5.1 Rising research investments and awareness campaigns to support market growth

TABLE 81 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.4.6 SOUTH KOREA

11.4.6.1 Rising R&D and promising clinical trials to positively impact market growth

TABLE 82 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.4.7 REST OF ASIA PACIFIC

TABLE 83 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.5 LATIN AMERICA

11.5.1 LATIN AMERICA: RECESSION IMPACT

TABLE 84 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)

TABLE 85 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

TABLE 86 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)

TABLE 87 LATIN AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)

TABLE 88 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 89 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)

11.5.2 BRAZIL

11.5.2.1 Modernization of healthcare facilities in Brazil to boost market

TABLE 90 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.5.3 MEXICO

11.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth in Mexico

TABLE 91 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.5.4 REST OF LATIN AMERICA

TABLE 92 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

11.6 MIDDLE EAST & AFRICA

11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH

TABLE 93 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)

TABLE 94 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)

TABLE 95 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)

TABLE 96 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)

TABLE 97 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)

11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE (Page No. - 133)

12.1 OVERVIEW

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TUMOR ABLATION MARKET

TABLE 98 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES

12.3 REVENUE ANALYSIS

FIGURE 37 REVENUE ANALYSIS OF TOP THREE PLAYERS IN TUMOR ABLATION MARKET (2021–2023)

12.4 MARKET SHARE ANALYSIS

FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)

TABLE 99 TUMOR ABLATION TECHNOLOGY MARKET: DEGREE OF COMPETITION

12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

FIGURE 39 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023

12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

12.5.5.1 Company footprint

FIGURE 40 TUMOR ABLATION MARKET: COMPANY FOOTPRINT

12.5.5.2 Technology footprint

TABLE 100 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT

12.5.5.3 Region footprint

TABLE 101 TUMOR ABLATION MARKET: REGION FOOTPRINT

12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

FIGURE 41 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023

12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

TABLE 102 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS

TABLE 103 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS

12.7 COMPANY VALUATION & FINANCIAL METRICS

12.7.1 FINANCIAL METRICS

FIGURE 42 EV/EBITDA OF KEY VENDORS

12.7.2 COMPANY VALUATION

FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

12.8 BRAND/PRODUCT COMPARISON

FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS

12.9 COMPETITIVE SCENARIO

12.9.1 PRODUCT LAUNCHES/APPROVALS

TABLE 104 TUMOR ABLATION MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2024

12.9.2 DEALS

TABLE 105 TUMOR ABLATION MARKET: DEALS, JANUARY 2021–MARCH 2024

12.9.3 EXPANSIONS

TABLE 106 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024

13 COMPANY PROFILES (Page No. - 148)

13.1 KEY PLAYERS

(Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats)*

13.1.1 MEDTRONIC PLC

TABLE 107 MEDTRONIC PLC: COMPANY OVERVIEW

FIGURE 45 MEDTRONIC PLC: COMPANY SNAPSHOT (2023)

TABLE 108 MEDTRONIC PLC: PRODUCTS OFFERED

TABLE 109 MEDTRONIC PLC: PRODUCT APPROVALS

13.1.2 JOHNSON & JOHNSON MEDTECH (ETHICON)

TABLE 110 JOHNSON & JOHNSON MEDTECH: COMPANY OVERVIEW

FIGURE 46 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)

TABLE 111 JOHNSON & JOHNSON MEDTECH: PRODUCTS OFFERED

13.1.3 STRYKER CORPORATION

TABLE 112 STRYKER CORPORATION: COMPANY OVERVIEW

FIGURE 47 STRYKER CORPORATION: COMPANY SNAPSHOT (2023)

TABLE 113 STRYKER CORPORATION: PRODUCTS OFFERED

TABLE 114 STRYKER CORPORATION: PRODUCT APPROVALS

TABLE 115 STRYKER CORPORATION: EXPANSIONS

13.1.4 VARIAN MEDICAL SYSTEMS, INC.

TABLE 116 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW

FIGURE 48 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2023)

TABLE 117 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED

TABLE 118 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES

TABLE 119 VARIAN MEDICAL SYSTEMS, INC.: DEALS

13.1.5 ANGIODYNAMICS, INC.

TABLE 120 ANGIODYNAMICS, INC.: COMPANY OVERVIEW

FIGURE 49 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2023)

TABLE 121 ANGIODYNAMICS, INC.: PRODUCTS OFFERED

TABLE 122 ANGIODYNAMICS, INC.: DEALS

13.1.6 BOSTON SCIENTIFIC CORPORATION

TABLE 123 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW

FIGURE 50 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)

TABLE 124 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED

13.1.7 EDAP TMS S.A.

TABLE 125 EDAP TMS S.A.: COMPANY OVERVIEW

FIGURE 51 EDAP TMS S.A.: COMPANY SNAPSHOT (2023)

TABLE 126 EDAP TMS S.A.: PRODUCTS OFFERED

13.1.8 MERMAID MEDICAL

TABLE 127 MERMAID MEDICAL: COMPANY OVERVIEW

TABLE 128 MERMAID MEDICAL: PRODUCTS OFFERED

13.1.9 CANYON MEDICAL INC.

TABLE 129 CANYON MEDICAL INC.: COMPANY OVERVIEW

TABLE 130 CANYON MEDICAL INC.: PRODUCTS OFFERED

13.1.10 OLYMPUS CORPORATION

TABLE 131 OLYMPUS CORPORATION: COMPANY OVERVIEW

FIGURE 52 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023)

TABLE 132 OLYMPUS CORPORATION: PRODUCTS OFFERED

TABLE 133 OLYMPUS CORPORATION: PRODUCT LAUNCHES

13.1.11 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.

TABLE 134 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW

TABLE 135 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED

13.1.12 MERIT MEDICAL SYSTEMS, INC.

TABLE 136 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW

FIGURE 53 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)

TABLE 137 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED

13.1.13 BIOVENTUS INC.

TABLE 138 BIOVENTUS INC.: COMPANY OVERVIEW

FIGURE 54 BIOVENTUS INC.: COMPANY SNAPSHOT (2023)

TABLE 139 BIOVENTUS INC.: PRODUCTS OFFERED

TABLE 140 BIOVENTUS INC.: DEALS

13.1.14 ICECURE MEDICAL LTD.

TABLE 141 ICECURE MEDICAL LTD.: COMPANY OVERVIEW

FIGURE 55 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)

TABLE 142 ICECURE MEDICAL LTD.: PRODUCTS OFFERED

TABLE 143 ICECURE MEDICAL LTD.: PRODUCT APPROVALS

TABLE 144 ICECURE MEDICAL LTD.: DEALS

13.1.15 CONMED CORPORATION

TABLE 145 CONMED CORPORATION: COMPANY OVERVIEW

FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT (2023)

TABLE 146 CONMED CORPORATION: PRODUCTS OFFERED

13.2 OTHER PLAYERS

13.2.1 MONTERIS MEDICAL

13.2.2 MIANYANG SONIC ELECTRONIC

13.2.3 RF MEDICAL

13.2.4 MINIMAX MEDICAL HOLDING GROUP

13.2.5 SONABLATE

13.2.6 ECO MEDICAL TECHNOLOGY (NANJING) CO., LTD.

13.2.7 STARMED CO., LTD.

13.2.8 SURGNOVA

13.2.9 CREO MEDICAL

13.2.10 MEDSPHERE SHANGHAI

*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

14 APPENDIX (Page No. - 190)

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

The study involved four major activities in estimating the current size of the tumor ablation market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial tumor ablation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the tumor ablation market. The primary sources from the demand side include hospitals, clinics, retailers, and other end users. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

Tumor Ablation Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The tiers of the companies are defined based on their total revenue. As of 2023: Tier 1 => USD 1 billion, Tier 2 = USD 200-500 million to USD 1 billion, and Tier 3 =< USD 200 million

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the tumor ablation market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

Generating a list of major global players operating in the tumor ablation market.
Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
Revenue mapping of major players to cover a major share of the global market share, as of 2022
Extrapolating the global value of the tumor ablation market industry

Bottom-up approach

In this report, the size of the global tumor ablation market was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the tumor ablation business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.

Approach 1: Company revenue estimation approach

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/product providers. This process involved the following steps:

Generating a list of major global players operating in the tumor ablation market
Mapping the annual revenues generated by major global players from the tumor ablation segment (or the nearest reported business unit/product category)
Mapping the revenues of major players to cover at least 50-55% of the global market share as of 2023
Extrapolating the global value of the tumor ablation industry

Market Size Estimation For Tumor Ablation: Approach 1 (Company Revenue Estimation)I

Tumor Ablation Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approach 2: Customer-based market estimation

During preliminary secondary research, the total sales revenue of tumor ablation was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

Generating a list of major customer facilities across each region and country
Identifying the average number of tumor ablation product supplies used by major customer facilities across each product type at the regional/country level, annually
Identifying the percentage contribution of major customer facilities to the overall tumor ablation expenditure and usage at the regional/country level, annually
Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually
Identifying the percentage contributions of individual market segments and subsegments to the overall tumor ablation market at the regional/country level

Tumor Ablation Market Size Estimation: Bottom-Up Approach

Tumor Ablation Market Size, and Share

Source: MarketsandMarkets Analysis

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global tumor ablation market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the tumor ablation market was validated using top-down and bottom-up approaches.

Market Definition

Tumor ablation is a minimally invasive surgical procedure used to remove or destroy cancerous tissue from the affected area as part of cancer management and treatment. The targeted tissue is subjected to ablating energy through surgical, laparoscopic, or percutaneous methods. This technique is commonly used for treating liver, bone, lung, kidney, prostate, and other types of cancer.

Key Stakeholders

Tumor ablation product manufacturers
Original equipment manufacturers (OEMs)
Suppliers, distributors, and channel partners
Healthcare service providers
Hospitals and academic medical centers
Interventional radiologists
Research laboratories
Health insurance providers
Government bodies/organizations
Regulatory bodies
Medical research institutes
Business research and consulting service providers
Venture capitalists and other public-private funding agencies
Market research and consulting firms

Objectives of the Study

To define, describe, and forecast the tumor ablation market based on technology, product type, mode of treatment, application, end user, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the revenue of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa
To profile the key players and comprehensively analyze their market ranking and core competencies
To benchmark players within the market using a proprietary competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of market share and product footprint

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global tumor ablation market report:

Product Analysis

Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Geographic Analysis

Further breakdown of the Rest of Europe tumor ablation market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
Further breakdown of the Rest of Asia Pacific tumor ablation market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
Further breakdown of the Rest of Latin America (RoLATAM), which comprises Argentina, Chile, Peru, Colombia, and Cuba

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.